SF
CRSP icon

Synovus Financial’s CRISPR Therapeutics CRSP Stock Holding History

Synovus Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20
Closed -$1K – 841
2020
Q2 		$1K Sell
20
-230
-92% -$13.4K ﹤0.01% 1474
2020
Q1 		$11K Buy
+250
New +$12.9K ﹤0.01% 1532
2019
Q4 		– Sell
-500
Closed -$20K – 1556
2019
Q3 		$20K Hold
500
– – ﹤0.01% 1087
2019
Q2 		$24K Hold
500
– – ﹤0.01% 984
2019
Q1 		$18K Hold
500
– – ﹤0.01% 1024
2018
Q4 		$14K Hold
500
– – ﹤0.01% 1028
2018
Q3 		$22K Buy
+500
New +$26.2K ﹤0.01% 1004

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Synovus Financial's CRSP Position: Q3 2020 in Review

Synovus Financial sold out of CRISPR Therapeutics (CRSP) in Q3 2020, closing a stake of 20 shares — an estimated $1K sold.

Synovus Financial first reported a position in CRSP in Q3 2018 and held it in 7 quarters. The position peaked at $24K in Q2 2019. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

  • Synovus Financial reported no remaining CRISPR Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Synovus Financial sold 20 CRISPR Therapeutics shares in Q3 2020, an estimated $1K.
  • Synovus Financial first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 7 quarters.
  • Synovus Financial's CRISPR Therapeutics position peaked at $24K in Q2 2019.
  • 310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.